Zibotentan is primarily investigated for its potential in treating cancer, particularly prostate cancer. It functions as an endothelin receptor antagonist, specifically targeting the endothelin A receptor. By blocking this receptor, zibotentan inhibits the signaling pathways that promote tumor growth and progression. This makes it a candidate for slowing the spread of cancer cells and reducing tumor size in advanced stages of prostate cancer. Clinical trials have explored its use both as a monotherapy and in combination with other treatments, such as chemotherapy or hormone therapy, to enhance efficacy. Its application is particularly focused on patients with metastatic castration-resistant prostate cancer, where it aims to improve survival rates and quality of life.